

Detection of *gyrA* ser83 mutation and *parC* gene amplification in *E.coli* and *Klebsiella pneumoniae* from tertiary care hospital, Puducherry

G. Muthu^{1,*}, T. Mangaiyarkarasi², Vishnuprabu³, E.Sathishkumar⁴, S. Srivani⁵

^{1,2}Scientist-C, ²Associate Professor, ³Scientist, ¹Model Rural Health Research Unit (NIE-ICMR/DHR), Linked to Tirunelveli Medical College, Primary Health Centre, Kallur, Tirunelveli, ²Sri Manakula Vinayagar Medical College and Hospital, Puducherry, ³Centre for Biotechnology, Anna University, Chennai, ^{4,5}Department of Microbiology, University of Madras, Chennai.

***Corresponding Author:**

Email: gopalmuthukrishnan@gmail.com

Abstract

Introduction: Fluoroquinolones are the broad spectrum antibiotics and recently the clinical isolates of *Enterobacteriaceae* species had slowly extend the high resistance towards them. The point mutation in *gyrA* gene had showed decreased susceptibility to ciprofloxacin and resistant to nalidixic acid. The aim of the present study was to identify *gyrA* and *parC* genes and *gyrA* ser83 mutation among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* by RFLP.

Methods: A total of 100 clinical strains of both *Escherichia coli* and *Klebsiella pneumoniae* were collected from tertiary care hospital from Pondicherry. All the strains were subjected to antimicrobial susceptibility pattern testing by disc diffusion method as per the Clinical Laboratory Standard Institute (CLSI2012). PCR based screening of *gyrA* and *parC* was carried out and additional analysis of *gyrA* ser83-phe mutation in *E.coli* and *K.pneumoniae* by agarose gel electrophoresis.

Results: Variation in both ciprofloxacin and nalidixic acid resistance were showed in the (100) clinical isolates of *E.coli* and *K.pneumoniae* were reported earlier. *GyrA* and *parC* genes were detected in both susceptible and resistant isolates of *E.coli* and *K.pneumoniae*. Among them, *E.coli* showed 100% (50/50) and *K.pneumoniae* showed 84% (42/50) positivity for *gyrA* while 78% (39/50) and 64% (32/50) positivity for *parC*. PCR-RFLP results indicated *gyrA* ser83 mutation in 84% (42/50) of *E.coli* and 66% (33/50). The results also shows that *E.coli* is less susceptible to fluoroquinolones compared to *K.pneumoniae*.

Conclusion: The overall resistance were increased for the ciprofloxacin and nalidixic acid among clinical isolates of *E.coli* and *K.pneumoniae* due to *gyrA* ser83-phe mutation. The antimicrobial resistance to fluoroquinolone drugs indicate the rapid genetic modifications undertaken by *Enterobacteriaceae* species and need for routine screening for resistance to develop next generation drugs.

Keywords: *E.coli*, *Klebsiella* species, Ciprofloxacin, *gyrA*, *parC* and PCR-RFLP.

Introduction

Among the *Enterobacteriaceae* species, the prevalence of resistance to fluoroquinolone is becoming a major problem in India. Fluoroquinolones and third and fourth generation cephalosporins are the most frequently prescribed antimicrobial agents for both gram negative and positive bacterial infections in all over the world.⁽¹⁾ However, antimicrobial resistance to drugs at present is increasing at an alarming rate, and is a global health concern, posing distinctive challenges to clinical microbiologists, clinicians, infection control professionals.

Fluoroquinolones resistance has increased in number in almost all gram negative bacteria, particularly in *E.coli*, *Klebsiella* species, *Salmonella* species etc.^(2,3) In recent years ESBL producing *E.coli* and *Klebsiella pneumoniae* have been increasing owing to infection and providing treatment to become a serious issue and also due to multi drug resistance (MDR). Eventhough fluoroquinolones are the effective drug for extended spectrum betalactamases producing *E.coli* and *Klebsiella pneumoniae* and also to treat the nosocomial, urinary tract infection, enteric fever and other bacterial infections.

Moreover, many studies reported that the ESBL-EK strains became susceptible to the fluoroquinolones drugs, also aspect of treatment these agents are very effective to them.⁽⁴⁾ Although a current studies have established that 40–45% of such isolates are resistant to fluoroquinolones.^(5,6)

An exposure and risk factors for fluoroquinolone resistant among ESBL-EK infection is most important and looks at the reason for the emergence of resistance. Fluoroquinolones are the most important drug which can have main role in treating ESBL-EK infection. In addition, consequently assist to reduce the dependence on other drugs like carbapenem and it can be limit the emergency of resistance in carbapenem drugs.

ESBL-producing strains have been shown to be significantly more frequent among ciprofloxacin-resistant *E. coli* than among ciprofloxacin-susceptible *E. coli* strains.⁽⁷⁾ Moreover, prior use of fluoroquinolones, an indwelling urinary catheter, and an invasive procedure within 72 hr prior to bacteraemia have been identified as independent risk factors for ciprofloxacin resistance in bloodstream infections due to ESBL *E. coli* and *Klebsiella* spp.⁽⁸⁻¹⁰⁾

Fluoroquinolones exert an antibacterial effect through inhibiting DNA synthesis by interacting with

DNA gyrase and topoisomerase IV. DNA gyrase which encoded by the genes such as *gyrA*, *gyrB* and topoisomerase IV encoded by *parC* and *parE*. One of the most important mechanisms of quinolone and fluoroquinolone resistance is to the substitutions of amino acid in the DNA gyrase and topoisomerase IV^(11,12) or to active efflux of the agent via antibiotic efflux pumps.⁽¹³⁾

Production of β -lactamase is the most common mechanism responsible for resistance to β -lactam antibiotics among the members of the *Enterobacteriaceae* family, which in turn is related to a single base mutation in *gyrA*, subunit of DNA gyrase that leads to amino acid and alteration of codons in the quinolone resistance determining regions (QRDR). Fluoroquinolones contain C-8 methoxy group and exhibit stronger antibacterial activity against bacteria that are resistant to quinolone due to *gyrA* mutation.⁽¹⁴⁾

The main objective of the present study is to find out the presence of *gyrA* ser83 mutation and *parC* gene amplification in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*.

Materials and Methods

Collection of clinical isolates of *E.coli* and *Klebsiella pneumoniae*:

A total of 100 clinical isolates of *E.coli* and *Klebsiella pneumoniae* were collected during 2012-2013 from SMV Medical College and Hospital, Pondicherry. Isolation and identification was carried out by standard microbiological techniques from 186 faecal specimens. Antibiotic susceptibility testing was carried out by disc diffusion method followed by Clinical Laboratory Standard Institute (CLSI 2012). The strains were stored in 0.5% of semisolid brain heart infusion medium along with 15% of glycerol at -20°C.

Extraction of genomic DNA: A single bacterial colony from overnight culture was suspended in 100 μ L of 50mM NaOH and incubated at 97°C for 3 minutes and immediately transferred to 4°C. After 5-10 minutes, 16 μ L of 1M of Tris-HCL was added and centrifuged at 8000rpm for 2 minutes. The supernatant containing bacterial genomic DNA was transferred to sterile tubes and stored at -20°C.⁽¹⁵⁾

Amplification of *gyrA* and *parC* genes by PCR: PCR Amplification of *gyrA* and *parC* genes: Template DNA prepared from bacterial strains as described above was amplified by PCR. The following primers were modified from,⁽¹⁶⁾ GyrA F: 5' ATG AGC GAC CTT GCG AGA GAA ATT ACA CCG 3' and GyrA R: 5' TTC CAT CAG CCC TTC AAT GCT GAT GAT GTC TTC 3' amplified *gyrA* gene fragment of length 630bp. The *parC* gene sequence was retrieved from NCBI database and sequence specific primers, ParC F: 5'ATG AGC GAT ATG GCA GAG CGC CTT GCG CTA 3' and

ParC R: 5' ACG CGC CGG TAA CAT TTT CGG TTC CTG CAT 3' were designed using Primer 3 online tool to amplify a 480bp gene fragment of *parC*. The primers were procured from Sigma Oligos, India. PCR was performed using Gene Amp 9700 thermal cycler (ABI USA) in final reaction volume of 50 μ L containing 5 μ L of 10x PCR buffer with MgCl₂ {NEB, USA}, 5 μ L of 10mM dNTP Mix (Takara, Japan), 2 μ L of 2 μ M forward and reverse primers, 0.25 μ L of Taq DNA polymerase (5U/ μ L) {NEB, USA}, 2.5 μ L of template DNA and 35.25 μ L of sterile water. The thermal conditions for the amplification of both *gyrA* and *parC* gene comprised one cycle of 2 min at 95°C, followed by 35 cycles of 45 sec at 94°C, 45 sec at 60°C and 30 sec at 72°C, with a final extension of 7 min at 72°C. The 10 μ L of PCR product was resolved in 1% (w/v) agarose gel (Sigma, India) prepared in 0.5X Tris Acetic acid EDTA (TAE) buffer and detected by ethidium bromide staining after electrophoresis (BioRad, USA). The 1000bp DNA ladder (Gibco BRL, USA) was used to refer the size of the PCR product in the gel. The gel was documented using gel documentation system (BioRad, USA).

Restriction digestion *gyrA* by *HinfI* enzyme: The amplified 630bp fragment of the *gyrA* gene has three *HinfI* restriction sites one of which lies at codon Ser83. The PCR product was digested for the detection of *gyrA* Ser83 mutation by *HinfI* enzyme. A volume of 20 μ L of precipitated PCR product was digested with 10 units of *HinfI* (New England Biolab-USA) at 37°C for 16hrs. The tubes were short spun after the complete digestion. Two percent agarose gel with ethidium bromide (50 μ g/ml) was prepared using 0.5xTAE buffer and 10 μ L of the *HinfI* digested PCR product was mixed with 2 μ L of 6x gel loading dye and resolved at 100V for 25 minutes using 0.5xTAE as a tank buffer; 5 μ L of 1000bp DNA ladder (Gibco Brl-USA) was used to refer the size of the digested fragments and documented using a gel documentation system (Bio Rad USA).

Result and Discussion

Analysis of ser83 mutation in *gyrA* and *parC* gene amplification: The *gyrA*(630bp)PCR product was detected in all *E.coli* isolates showing 100% (50/50) positivity and 84% (42/50) positivity in *K.pneumoniae* strains(Fig.1). While *parC* (480bp) were identified only in 78% (39/50) of *E.coli* and 64% (32/50) in *K.pneumoniae* strains (Fig-2). The *gyrA* (630bp) gene contains three *HinfI* restriction sites, one of which present at the codon 83 serine (TCC), when mutated to phenylalanine (TTC) leads to loss of the restriction site. The *gyrA* (630bp) PCR product with codon83 mutation due to loss of one restriction site, *HinfI* digestion results in three fragment of length 343bp, 149bp and 138bp involved in nalidixic acid resistant strains (Fig-3). Analysis of *gyrA* product digested with *HinfI* enzyme

which showed that 84% (42/50) of *E.coli* and 66% (33/50) of *K.pneumoniae*.

Resistance rate of ESBL producing as well as fluoroquinolone resistant isolates of *E.coli* and *K.pneumoniae* are increasing in hospital and community settings. Moreover, resistance to imipenem and meropenem have been reported, which would further complicate the treatment regimen, as these are the latest generation of broad spectrum antibiotics used against drug-resistant pathogenic bacteria, as well as in the empiric therapy of critically ill patients. Resistance percentages of 32 to 89% have confirmed by the MIC values against five fluoroquinolone antibiotics.

Enterobacteriaceae family of organisms were more resistance to quinolone and fluoroquinolone drugs and patients with intra abdominal infections, acquiring resistance with nosocomial infections in order to cover the entire spectrum of potential pathogens. In Asian countries, an alarming resistance of >60% to ampicillin-sulbactam or a quinolone and ESBL-producing strain is observed.⁽¹⁷⁻¹⁹⁾ ESBL producing *E.coli* and *K.pneumoniae* were highly reported with different rate of prevalence ranging from New Zeland (4.4%), 77.4% in India and vastly varied in Asian Pacific regions. Whereas the ESBL production was detected in USA in different frequency from 4.7% and 17.5% of *E. coli* and *K. pneumoniae* isolates, respectively. The other studies they have reported that 17% and 27% of the strains of *E.coli* and *Klebsiella pneumoniae* were producing ESBL respectively, were susceptible to ciprofloxacin.⁽¹⁷⁾ We have earlier reported, 48% nalidixic acid and 32% ciprofloxacin resistance in *E.coli* and *Klebsiella pneumoniae* that is concordant with 32 to 89% of resistance documented by other findings.⁽²⁰⁾

Moreover, the decreased susceptibility to ciprofloxacin and resistance to nalidixic acid clinical isolates of *E.coli* and *Klebsiella pneumoniae* were fall on to *gyrA* serine 83 mutation and which is most frequently altered amino acid and phenyl alanine is the most common substitution.⁽¹²⁾

It is hereby confirm that the single amino acid substitution at position 83 confers increased resistance than at position 87, however the further mutations in *gyrA* or other genes are essential for the development of high-level fluoroquinolone resistance.⁽²¹⁾

Conclusion

Among the Enterobacteriaceae, both *E.coli* and *Klebsiella species* had enormous infection dynamics and resistance to fluoroquinolones. Most predominantly both *E.coli* and *Klebsiella spp* strains were resistant to a greater number of antibiotics, and the percentage of resistance values for each antibiotic were higher with the isolated strains. The present study confirms the emerging trend of fluoroquinolone resistance due to single point mutation in *gyrA* gene. We also observed *E.coli* is comparatively less susceptible to fluoroquinolone.

Further studies are required to alter the mutated gene to its wild type and to study the interrelationships between compensatory mutations, fluoroquinolone resistance and DNA supercoiling.




Fig. 1: Agarose showing the *gyrA* PCR product (630bp)




Fig. 2: Agarose gel showing the *parC* PCR product (480bp)




Fig. 3: RFLP electrophoretic gel showing *gyrA* PCR product digested with *HinfI*

References

- Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin.Microbiol. Rev* (2001) 14,933–951.
- Acar, J. F. Trends in bacterial resistance to fluoroquinolones. *Clin.Infect Dis* (1997) 24 (Suppl. 1):S67–73.
- Hooper, D. C. Clinical applications of quinolones. *Biochim. Biophys. Acta*1400 (1998) 45–61.
- Karas JA, Pillay DG, Muckart D. Treatment failure due to extended-spectrum b-lactamase (letter). *J Antimicrob Chemother* (1996) 37, 203–4.
- Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. *Clin Infect Dis*1996;23:779–84.
- Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant *Klebsiella spp.* and *Escherichia coli* in nursing homes. *JAMA* (1999) 281, 517–23.

7. Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D, Catal C, Anđ-Küçüker M, Anđ O: Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in *Escherichia coli* and *Klebsiella pneumoniae* strains. Clin Microbiol Infect (2004) 10,72-75.
8. Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW: Community-acquired versus nosocomial *Klebsiella pneumoniae* bacteriemia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci (2006) 21, 816-822.
9. Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH: Risk factors of ciprofloxacin resistance in urinary *Escherichia coli* isolates. J Microbiol Immunol Infect (2008) 41, 325-331.
10. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J: Relationship between quinolones use and emergence of ciprofloxacin-resistant *Escherichia coli* in bloodstream infections. Antimicrob Agents Chemother (1995) 39, 520-524.
11. Ruiz, J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. (2003) 51, 1109–1117.
12. Hopkins, K. L., Davies, R. H., and Threlfall, E. J. Mechanisms of quinolone resistance in *Escherichia coli* and *Salmonella*: recent developments. Int. J. Antimicrob. Agents (2005) 25, 358–373.
13. Kohler, T., and J.-C. Pechere. Bacterial resistance to quinolones: mechanisms and clinical implications, (1998) 117–142. In V. T. Andriole (ed.), The quinolones. Academic Press, London, United Kingdom.
14. Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K: Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of staphylococcus aureus. Antimicrob Agents Chemother (2001) 45, 2703–2709.
15. Hartas J, Hibble M, Sriprakash KS. Simplification of a locus-specific DNA typing method (Vir Typing) for *Streptococcus pyogenes*. J Clin Microbiol (1998) 36, 1428-29.
16. Renuka K, Kapil A, Kabra SK, Wig N, Das BK, Prasad VV, Chaudhry R, Seth P. Reduced susceptibility to ciprofloxacin and *gyrA* gene mutation in North Indian strains of *Salmonella enterica serotype Typhi* and *serotype Paratyphi A*. Microb Drug Resist (2004) 10, 146-53.
17. S. P. Hawser, S. K. Bouchillon, D. J. Hoban, R. E. Badal, P. R. Hsueh, and D. L. Paterson, "Emergence of high levels of extended-spectrum-β-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007," Antimicrobial Agents and Chemotherapy, (2009) 53, 3280–3284.
18. D. Yagci, F. Yoruk, A. Azap, and O. Memikoglu, "Prevalence and risk factors for selection of quinolone-resistant *Escherichia coli* strains in fecal flora of patients receiving quinolone therapy," Antimicrobial Agents and Chemotherapy (2009) 53, 1287–1289.
19. J. Rodríguez-Baño, E. Picon, P. Gijon et al., "Community-onset bacteremia due to extended-spectrum β-lactamase-producing *Escherichia coli*: risk factors and prognosis," Clinical Infectious Diseases, (2010) 50, 40–48.
20. Muthu G, Tamil Iniyan G, Shanmugam J and Mangaiyarkarasi T. Molecular detection of blaCTX-M and blaSHV genes in *E.coli* and *Klebsiella pneumoniae* in a tertiary care hospital in Puducherry, India. Int J Pharm Bio Sci. (2014) 5(1), 689-96.
21. Johnning A, Kristiansson E, Fick J, Weijdegård B and Larsson DGJ Resistance Mutations in *gyrA* and *parC* are Common in *Escherichia* Communities of both Fluoroquinolone-Polluted and Uncontaminated Aquatic Environments. Front. Microbiol (2015) 6, 1355.